Conference

2 Day Flow Cytometry Innovations Conference 2023: Washington, United States - May 4-5, 2023 - Focus Upon Single Cell Analysis as a Key Element Coupled with Single Extracellular Vesicle (EV) Analysis

Retrieved on: 
Friday, March 24, 2023
University of Missouri College of Engineering, University of Southern California, University of Victoria, Centre for Cellular and Molecular Platforms, Yale University, La Jolla Institute for Immunology, University, EV, College, Exhibition, Associate professor, University of Kansas, Seattle Children's, University of Washington, Mechanical engineering, Personalized medicine, Analysis, Biomedical engineering, Canada Research Chair, Chemical substance, University of California, Los Angeles, Flow cytometry, Royal Army Medical Corps, Novo Nordisk, ISCB Senior Scientist Award, Biological engineering, Research institute, Sorter, University of California, Berkeley, Conference, Microfluidics, Beauty salon, Mobile phone, Mail order, Furniture, Management, Ridesharing, Science, Engineering, Professor, Chemistry, Medicine

DUBLIN, March 24, 2023 /PRNewswire/ -- The "Innovations in Flow Cytometry 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 24, 2023 /PRNewswire/ -- The "Innovations in Flow Cytometry 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Innovations in Flow Cytometry 2023 Conference being held May 4-5, 2023 in Seattle.
  • This conference is part of a 2-track event with the companion track being co-located and being held concurrently, entitled Innovations in Microfluidics 2023.
  • We focus upon Single Cell Analysis as a key element of this event coupled with Single Extracellular Vesicle (EV) Analysis.

CancerIQ Unveils New Service Offerings and Integrated Risk Score Calculator at NCoBC 2023

Retrieved on: 
Friday, March 24, 2023
High Risk, Booth, Cancer, Risk assessment, Risk, NCCN, Genetic counseling, Magnetic resonance imaging, Patient, EHR, Chemoprophylaxis, Breast MRI, HL7, Conference, Success, Medical imaging, Nursing

CHICAGO, March 24, 2023 /PRNewswire-PRWeb/ -- CancerIQ will showcase its latest precision cancer prevention and early detection offerings for breast centers at the 32nd Annual Interdisciplinary Breast Center Conference (NCoBC 2023) in Las Vegas, March 24-28, (Booth #301). The company will offer NCoBC attendees an exclusive first look at two exciting new offerings: CancerIQ Complete, the industry's first full-service suite designed to help breast centers start, run and grow high-risk breast programs; and a new real-time, EHR-initiated CancerIQ Risk Calculator.

Key Points: 
  • The company will offer NCoBC attendees an exclusive first look at two exciting new offerings: CancerIQ Complete, the industry's first full-service suite designed to help breast centers start, run and grow high-risk breast programs; and a new real-time, EHR-initiated CancerIQ Risk Calculator.
  • CancerIQ helps providers traverse the challenges of managing population-wide cancer risk assessment to offer more personalized, evidence-based care pathways that lead to early cancer detection and prevention.
  • The new Risk Score Calculator brings comprehensive risk assessment into leading EHR workflows.
  • CancerIQ is proudly sponsoring the High Risk IT Forum in the Pre-Conference High Risk Breast Program: Essentials for Success.

Food Industry Announces Significant Progress Toward Achieving Hunger and Nutrition Goals

Retrieved on: 
Friday, March 24, 2023
Public Policy, Government, White House, Federal Government, Other Policy Issues, Supermarket, Supply Chain Management, Food, Beverage, Retail, White House Conference on Food, Nutrition, and Health, Dietary Guidelines for Americans, Shared memory, Multimedia, Nutrition and Health, White, Congress, National Strategy for Inner Areas, Food industry, White House conference, FMI, Feeding America, Health, Conference, Agriculture, Grocery store, Hunger

In conjunction with today’s “ White House Challenge to End Hunger and Build Healthy Communities Kickoff ” event, FMI – The Food Industry Association is pleased to highlight the industry’s commitments and efforts underway in addressing hunger and improving nutrition and health spurred by the White House Conference on Hunger, Nutrition and Health convened in September 2022.

Key Points: 
  • In conjunction with today’s “ White House Challenge to End Hunger and Build Healthy Communities Kickoff ” event, FMI – The Food Industry Association is pleased to highlight the industry’s commitments and efforts underway in addressing hunger and improving nutrition and health spurred by the White House Conference on Hunger, Nutrition and Health convened in September 2022.
  • View the full release here: https://www.businesswire.com/news/home/20230324005237/en/
    FMI - The Food Industry Association and our member companies have committed to donating two billion meals in 2023 to combat hunger in the United States.
  • Nearly six months after the White House Conference, FMI members have expanded their food donation efforts and health and well-being programs.
  • Grocery stores serve as accessible, convenient, community-based destinations for feeding assistance, preventive care, nutrition guidance, and nourishing, practical meal solutions.

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 24, 2023
Migraine, IPO, SG, Pharmacy, Marketing, Bank statement, AAN, IMPL, Headache (journal), AHS, Prescription, American Academy, GAAP, DHE, R, The Journal of Headache and Pain, Journal, Patient, Administration, Manuscript, Host, Otorhinolaryngology, Webcast, Growth, Research and development, American Academy of Neurology, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Safety, Video game, Cryptocurrency, Pharmaceutical industry, Health insurance, Headache, Dihydroergotamine, Pain, Q4, Impeller

SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Key Points: 
  • ET
    SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  • New Trudhesa prescriptions increased by 24 percent from Q3 to Q4 2022 driven by an expanded, more efficient salesforce.
  • Reimbursement of all shipments is 60 percent for the fourth quarter 2022.
  • ET today to discuss the fourth quarter and full year 2022 financial results and provide a corporate and business update.

Tile of Spain Companies Showcase Ground-Breaking Innovations and Trends During the 39th Edition of CEVISAMA

Retrieved on: 
Friday, March 24, 2023
Interior, Weather, System, International Fair, Multimedia, Atmosphere, Conference, Safety, Tile

MIAMI, March 24, 2023 /PRNewswire/ -- Tile of Spain manufacturers returned to Valencia, Spain last month for the highly anticipated return of CEVISAMA , the International Fair for Ceramic Tiles and Bathroom Furnishings.

Key Points: 
  • MIAMI, March 24, 2023 /PRNewswire/ -- Tile of Spain manufacturers returned to Valencia, Spain last month for the highly anticipated return of CEVISAMA , the International Fair for Ceramic Tiles and Bathroom Furnishings.
  • This year's annual event was held from February 27 - March 3, 2023 at Feria Valencia, located in Valencia's center city.
  • The Spanish tile industry surpassed expectations with overall sales increasing by 16.2% since last year, with approximately 50% of all sales made abroad.
  • Manufacturers are building complex glazed surfaces by putting a single piece of tile through the kiln three to four times.

Recon Technology, Ltd Reports Financial Results for the First Six Months of Fiscal Year 2023

Retrieved on: 
Friday, March 24, 2023
Plastic, Marketing, Recon, Internet of things, COVID-19, Research, COVID, China Securities Regulatory Commission, Internet, Acquisition, Risk, COVID 19, Growth, Heat, Conference, Automation, Software, Security (finance), Cryptocurrency

As a result, our revenue for the first six months ended December 31, 2022 decreased by 16.3% compared to the same period of year 2021.

Key Points: 
  • As a result, our revenue for the first six months ended December 31, 2022 decreased by 16.3% compared to the same period of year 2021.
  • First Six Months Fiscal 2023 Financial Results:
    Total revenues for the six months ended December 31, 2022 were approximately RMB45.6 million ($6.6 million), a decrease of approximately RMB8.8 million ($1.3 million) or 16.3% from RMB54.4 million for the same period in 2021.
  • Gross profit margin increased slightly to 28.8% for the six months ended December 31, 2022 from 26.7% for the same period in 2021.
  • On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business.

Aristocrat Gaming Selects Inspired Entertainment for Virtual Sports Offering Through National Football League (NFL) License

Retrieved on: 
Friday, March 24, 2023
NFL, Bowl game, Partnership, AFC, Super Bowl, AFL, National Football League, Aristocrat Leisure, Conference, Inspiration

LAS VEGAS, March 24, 2023 /PRNewswire/ -- Aristocrat Gaming™ announced today that they have chosen Inspired Entertainment, Inc. (NASDAQ: INSE) as their partner to bring a new virtual sports experience to football fans worldwide through Aristocrat Gaming's multi-year, global licensing agreement with the National Football League (NFL).

Key Points: 
  • LAS VEGAS, March 24, 2023 /PRNewswire/ -- Aristocrat Gaming™ announced today that they have chosen Inspired Entertainment, Inc. (NASDAQ: INSE) as their partner to bring a new virtual sports experience to football fans worldwide through Aristocrat Gaming's multi-year, global licensing agreement with the National Football League (NFL).
  • The NFL-themed virtual sports simulations will provide fans the ability to wager on teams as they go head-to-head in fast-paced, ultra-realistic simulated matchups.
  • Users will see many of the same wagering options as a standard sportsbook including money line bets, over/under total score and total touchdowns.
  • "Through Inspired, this NFL license expansion into virtual sports presents a ground-breaking entertainment option that's never been done before," said Hector Fernandez, Aristocrat Gaming CEO.

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Friday, March 24, 2023
Conference, Inflammation, Pharmaceutical industry, Broadcasting

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

Key Points: 
  • ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.
  • A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com .
  • A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

Quantum-Si to Participate in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference

Retrieved on: 
Friday, March 24, 2023
Research, Technology, Semiconductor, Genetics, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Proteomics, Protein sequencing, Blueprint, Quantum, Innovation, Doctor of Philosophy, Conference, Drug discovery

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference to be held on Thursday, April 6, 2023.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference to be held on Thursday, April 6, 2023.
  • Patrick Schneider, Ph.D., Quantum-Si’s President and Chief Operating Officer, will participate in the panel discussion “How to Translate Insights from Proteomics and Advances in AI into Drug Discovery and Innovation?” at 10:30 AM ET.
  • Additionally, Jeff Hawkins, Quantum-Si’s Chief Executive Officer, and Dr. Schneider will participate in a fireside chat at 2:30 PM ET.

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

Retrieved on: 
Friday, March 24, 2023
Yale University, Mitochondrion, PTC Therapeutics, Drug development, University, Gene, The Conference Board, Conference call, PTC, Cancer, Eladocagene exuparvovec, Coronavirus Scientific Advisory Board, European Research Advisory Board, Brain, CMO, RNA, History, CNS, DSM-IV codes, EMA, Bachelor of Arts in Clinical Psychology, Biosensors and Bioelectronics, Shriners Hospitals for Children, ET, Retirement, Oxidative stress, Consultant, Patient, University of Washington Department of Global Health, Stuart, Growth, Mitochondrial disease, Rare, Therapy, Scientific Advisory Group for Emergencies, Conference, Stu, Management, Pharmaceutical industry, Vaccine, Nursing

SOUTH PLAINFIELD, N.J., March 24, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT). Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years. Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development. Under his leadership, PTC has grown from a research organization with expertise in the control of RNA processes to a publicly traded, integrated, global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of neurological and neuromuscular disorders, metabolic disorders, and cancer.

Key Points: 
  • Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years.
  • Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development.
  • What Stuart and the team have achieved in 25 years is extraordinary," said Michael Schmertzler, Chairman of the Board of Directors.
  • Matthew Klein, M.D., M.S., F.A.C.S., current Chief Operating Officer, has been named the company's CEO and will join the Board of Directors.